Advertisement
UK markets open in 2 hours 6 minutes

  • NIKKEI 225

    37,102.46
    -977.24 (-2.57%)
     

  • HANG SENG

    16,184.02
    -201.85 (-1.23%)
     

  • CRUDE OIL

    84.25
    +1.52 (+1.84%)
     

  • GOLD FUTURES

    2,396.10
    -1.90 (-0.08%)
     

  • DOW

    37,775.38
    +22.07 (+0.06%)
     

  • Bitcoin GBP

    50,259.58
    +647.24 (+1.30%)
     

  • CMC Crypto 200

    1,294.71
    +409.17 (+45.35%)
     

  • NASDAQ Composite

    15,601.50
    -81.87 (-0.52%)
     

  • UK FTSE All Share

    4,290.02
    +17.00 (+0.40%)
     
Money:

Best mortgage deals of the week

As possibility of multiple interest rate cuts dwindle here's what banks and building societies are offering

Europe backs new leukaemia drugs from J&J and Gilead

Reuters - UK Focus

LONDON, July 25 (Reuters) - Two new leukaemia drugs from Johnson & Johnson (NYSE: JNJ - news) and Gilead Sciences (NasdaqGS: GILD - news) have been recommended for approval by European regulators, paving the way for formal approval in a couple of months.

The European Medicines Agency said on Friday its experts had issued positive opinions for J&J's ibrutinib, developed with Pharmacyclics (NasdaqGS: PCYC - news) , and Gilead's idelalisib.

Ibrutinib, marketed at Imbruvica, was approved by U.S. regulators for treatment of chronic lymphocytic leukaemia (CLL) in February, while Gilead's idelalisib, which has the brand name Zydelig, was approved in the United States last month.

The approvals reflect a rapid pace of progress in treating CLL, a slowly progressing form of blood cancer, as scientists develop better ways to target the biological pathways involved in the disease.

Last November, the U.S. Food and Drug Administration also approved Roche's Gazyva and the use of Arzerra, from GlaxoSmithKline (Other OTC: GLAXF - news) and Genmab (Other OTC: GMXAY - news) , was expanded in April 2014 to include CLL. (Reporting by Ben Hirschler; editing by Tom Bergin)